CKF Tide Tables

Retatrutide

Quick Facts

Property Value
Category Triple Agonist Metabolic Peptide
Risk Level High
Administration Subcutaneous Injection
Typical Frequency Weekly
Estimated Half-Life Approximately 6 Days
Primary Research Interest Weight Loss / Appetite Suppression / Metabolic Health
Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and metabolic compounds. Retatrutide is a potent biologically active triple agonist peptide capable of significantly altering glucose regulation, appetite signaling, gastrointestinal function, and metabolic pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Reconstitution Guide

  • Vial Size: 60 mg
  • Dilutant Type: BAC Water
  • Amount of Dilutant Added: 3 mL
  • Final Concentration: 20.00 mg/mL

At this concentration:

• 1 mg = 0.050 mL (5.0 units)

• 2 mg = 0.100 mL (10.0 units)

• 4 mg = 0.200 mL (20.0 units)

• 6 mg = 0.300 mL (30.0 units)

• 12 mg = 0.600 mL (60.0 units)

2. Route of Administration

Retatrutide is most commonly administered as a subcutaneous injectable metabolic peptide.

  • Primary Route: SubQ Injection
  • Preferred Timing: Flexible weekly administration timing
  • Administration Notes: Slow titration schedules are commonly emphasized in order to reduce gastrointestinal side effects

3. Typical Research Protocols

  • Product Strength: 20.00 mg/mL
  • Typical Delivered Amount: Weeks 1–4: 1–2 mg once weekly; Weeks 5–8: 2–4 mg once weekly; Weeks 9–12: 4–6 mg once weekly; Advanced range: 6–12 mg weekly
  • Frequency: Weekly
  • Cycle Length: Indefinite
  • Special Notes: None

4. Summary

Retatrutide is an experimental triple agonist peptide designed to simultaneously target GLP-1, GIP, and glucagon receptors.

Research interest in Retatrutide primarily centers around aggressive weight loss, appetite suppression, glucose regulation, and metabolic health optimization.

5. Mechanism of Action

Retatrutide functions through simultaneous activation of multiple metabolic hormone receptors:

  • GLP-1 receptor activation for appetite suppression and slowed gastric emptying
  • GIP receptor activation for insulin and metabolic signaling modulation
  • Glucagon receptor activation for increased energy expenditure and fat metabolism signaling
  • Substantial appetite suppression
  • Enhanced fat loss signaling
  • Improved glucose regulation
  • Reduced caloric intake
  • Increased metabolic expenditure

6. Potential Benefits

  • Potential rapid body fat reduction
  • Powerful appetite suppression
  • Improved glucose control
  • Enhanced metabolic health markers
  • Potential cardiovascular risk factor improvement
  • Possible improvements in insulin sensitivity

7. Potential Risks / Side Effects

High

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Severe appetite suppression
  • Muscle loss during aggressive weight reduction
  • Gallbladder complications
  • Pancreatitis concerns
  • Potential hypoglycemia risk

8. Half-Life

Retatrutide is commonly discussed as having an estimated half-life of approximately 6 days.

This extended duration supports once-weekly administration protocols.

9. Storage Information

  • Store refrigerated before and after reconstitution
  • Protect from direct light exposure
  • Avoid repeated freeze-thaw cycles
  • Maintain sterile handling practices during preparation

10. Contraindications / Warnings

  • History of pancreatitis
  • Gallbladder disease
  • Pregnancy or breastfeeding
  • Severe gastrointestinal disorders
  • Personal or family history of medullary thyroid carcinoma

11. Research References

  • PubMed
  • NIH Publications
  • Metabolic peptide literature
  • Peer-reviewed endocrinology journals